entertainment -WSS

entertainment

author：fashion 2025-08-04 03:40:18 - browse：624

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Popular nasal decongestant doesn't actually relieve congestion

WSS

Doctors increasingly discourage vaping amid mounting health concerns

Europe is fastest

HCA says smaller share of spending going to labor

New weight loss drugs vying to be the next Wegovy or Mounjaro

IRA could hurt research into orphan drugs for rare diseases

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

entertainment

entertainment

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Snowpack in the West is melting rapidly. Where will all that extra water go?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Will the IRA bring competition to the biologics market?

In Memoriam: Notable people who died in 2023

Private equity could exacerbate cardiology's overuse problem, experts fear

Hepatitis C has a cure — but many Americans still lack access to it

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Peter Hotez and the public health issue of online harassment

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

focus

What AstraZeneca

Europe is fastest

Poland's lawmakers approve a divisive law on Russian influence

Popular nasal decongestant doesn't actually relieve congestion

Private equity could exacerbate cardiology's overuse problem, experts fear

Snowpack in the West is melting rapidly. Where will all that extra water go?

knowledge

entertainment

Wikipedia

focus